RBM5 reduces small cell lung cancer growth, increases cisplatin sensitivity and regulates key...

Area of Science:

• Oncology
• Molecular Biology
• Cancer Genetics

Background:

• Small cell lung cancer (SCLC) is highly aggressive with poor prognosis.
• The tumor suppressor gene RBM5 is downregulated in many cancers, but its role in SCLC is unclear.

Purpose of the Study:

• To investigate the function of RBM5 in SCLC.
• To determine the effects of RBM5 re-expression on SCLC cell lines and patient specimens.

Main Methods:

• Utilized SCLC cell line (GLC20) with RBM5 deletion to create stable RBM5-expressing sublines.
• Performed transcriptome and target identification studies.
• Conducted RNA sequencing on paired SCLC patient tumor and non-tumor samples.
• Performed functional studies on cell growth and chemosensitivity.

Main Results:

• RBM5 re-expression regulated cell cycle and apoptosis in SCLC cells.
• RBM5 significantly downregulated angiogenesis and cell adhesion pathways.
• Decreased RBM5 expression was observed in SCLC patient tumors, correlating with pathway alterations seen in cell lines.
• RBM5 expression slowed SCLC cell growth and enhanced cisplatin sensitivity.

Conclusions:

• RBM5 plays a crucial role in maintaining the non-transformed state of lung cells.
• RBM5 deletion contributes to SCLC development and progression.
• RBM5 re-expression represents a potential therapeutic strategy for SCLC.